세계의 바이러스 벡터 제조 시장 규모, 점유율, 동향, 예측 : 유형, 질환, 용도, 최종사용자, 지역별(2025-2033년)

The global viral vector manufacturing market size was valued at USD 1,469.6 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 8,512.2 Million by 2033, exhibiting a CAGR of 21.6% from 2025-2033. North America currently dominates the market, holding a market share of over 49.3% in 2024. The rising prevalence of genetic disorders, increasing adoption of gene therapies, advanced biotechnology infrastructure, expanding clinical trials, strong government funding, robust R&D investments, and the presence of leading pharmaceutical companies drive the viral vector manufacturing market in North America.

A viral vector is a tool used by molecular biologists for delivering genetic materials into cells. It is used to replace defective genes for curing genetic disorders and express and present pathogenic antigens for generating an immune response by mimicking a natural infection. It is widely employed in oncolytic therapies to target and kill tumor cells. Besides this, as it assists in treating different diseases, such as heart defects, metabolic diseases, and neurodegenerative disorders, it finds extensive applications in life science research, gene therapy and vaccinology. At present, there is a rise in viral vector manufacturing on account of the rising prevalence of genetic disorders due to a combination of gene mutations and damaged chromosomes in the body.

Viral Vector Manufacturing Market Trends:

The increasing cancer patients due to the rising alcohol consumption and sedentary lifestyles of individuals represents one of the key factors contributing to the growth of the market. In addition, there is a rise in the number of clinical studies undertaken on viral vectors across the globe. This, along with the growing utilization of viral vectors in novel drug delivery, is positively influencing the market. Besides this, they are efficient carriers of virus-disabling sequences and are used to deliver HIV-inhibiting transgenes to human hematopoietic stem cells (HSCs). Additionally, governments of several countries are launching campaigns to generate awareness about viral vector vaccines among individuals. They are also improving the regulatory environment via changes, such as fast-track approval processes. Furthermore, key market players are extensively investing in capacity expansion for manufacturing activities around the world. These players are also indulging in mergers and acquisitions (M&A), which is projected to increase their overall sales and profitability.

Key Market Segmentation:

Breakup by Type:

• Adenoviral Vectors
• Adeno-associated Viral Vectors
• Lentiviral Vectors
• Retroviral Vectors
• Others

Breakup by Disease:

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others

Breakup by Application:

• Gene Therapy
• Vaccinology

Breakup by End User:

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V.

Key Questions Answered in This Report

• 1.What is viral vector manufacturing?
• 2.How big is the global viral vector manufacturing market?
• 3.What is the expected growth rate of the global viral vector manufacturing market during 2025-2033?
• 4.What are the key factors driving the global viral vector manufacturing market?
• 5.What is the leading segment of the global viral vector manufacturing market based on type?
• 6.What is the leading segment of the global viral vector manufacturing market based on disease?
• 7.What is the leading segment of the global viral vector manufacturing market based on application?
• 8.What are the key regions in the global viral vector manufacturing market?
• 9.Who are the key players/companies in the global viral vector manufacturing market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Viral Vector Manufacturing Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Adenoviral Vectors
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Adeno-associated Viral Vectors
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Lentiviral Vectors
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Retroviral Vectors
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Disease

• 7.1 Cancer
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Genetic Disorders
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Infectious Diseases
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Application

• 8.1 Gene Therapy
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Vaccinology
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by End User

• 9.1 Pharmaceutical and Biopharmaceutical Companies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Research Institutes
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Cognate BioServices Inc. (Charles River Laboratories International Inc.)
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 F. Hoffmann-La Roche AG
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
  • 15.3.3 FinVector Oy
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 FUJIFILM Holdings Corporation
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Kaneka Eurogentec S.A. (Kaneka Corporation)
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Lonza Group AG
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 Merck KGaA
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Oxford Biomedica plc
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 REGENXBIO Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Sanofi S.A.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Thermo Fisher Scientific Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 uniQure N.V.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials